Regulatory B Lymphocytes Colonize the Respiratory Tract of Neonatal Mice and Modulate Immune Responses of Alveolar Macrophages to RSV Infection in IL-10-Dependant Manner.
Animals
Animals, Newborn
B-Lymphocyte Subsets
/ immunology
B-Lymphocytes, Regulatory
/ immunology
Cells, Cultured
Immunity, Innate
Interferon Type I
/ biosynthesis
Interleukin-10
/ immunology
Lung
/ immunology
Macrophages, Alveolar
/ immunology
Mice
Mice, Inbred BALB C
Respiratory Syncytial Virus Infections
/ immunology
Respiratory Syncytial Viruses
/ immunology
Spleen
/ immunology
Turbinates
/ immunology
Virus Replication
age-dependent replication
alveolar macrophage
immunoregulation
innate immunity
interferons
interleukine-10
lungs
neonates
regulatory B-cell
respiratory syncytial virus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
29 07 2020
29 07 2020
Historique:
received:
10
07
2020
revised:
24
07
2020
accepted:
25
07
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
24
2
2021
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) is the prevalent pathogen of lower respiratory tract infections in children. The presence of neonatal regulatory B lymphocytes (nBreg) has been associated with a poor control of RSV infection in human newborns and with bronchiolitis severity. So far, little is known about how nBreg may contribute to neonatal immunopathology to RSV. We tracked nBreg in neonatal BALB/c mice and we investigated their impact on lung innate immunity, especially their crosstalk with alveolar macrophages (AMs) upon RSV infection. We showed that the colonization by nBreg during the first week of life is a hallmark of neonatal lung whereas this population is almost absent in adult lung. This particular period of age when nBreg are abundant corresponds to the same period when RSV replication in lungs fails to generate a type-I interferons (IFN-I) response and is not contained. When neonatal AMs are exposed to RSV in vitro, they produce IFN-I that in turn enhances IL-10 production by nBreg. IL-10 reciprocally can decrease IFN-I secretion by AMs. Thus, our work identified nBreg as an important component of neonatal lungs and pointed out new immunoregulatory interactions with AMs in the context of RSV infection.
Identifiants
pubmed: 32751234
pii: v12080822
doi: 10.3390/v12080822
pmc: PMC7472339
pii:
doi:
Substances chimiques
IL10 protein, mouse
0
Interferon Type I
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Innate Immun. 2016;8(5):452-63
pubmed: 27423203
Viruses. 2020 May 04;12(5):
pubmed: 32375305
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1619-24
pubmed: 22307620
Viruses. 2020 May 08;12(5):
pubmed: 32397226
Immunity. 2017 Feb 21;46(2):301-314
pubmed: 28228284
PLoS Pathog. 2015 Oct 16;11(10):e1005217
pubmed: 26473724
J Exp Med. 2013 Sep 23;210(10):1977-92
pubmed: 24043763
Mol Immunol. 2017 Jul;87:284-292
pubmed: 28531812
Blood. 2002 Dec 15;100(13):4537-43
pubmed: 12393419
J Exp Med. 2007 May 14;204(5):1107-18
pubmed: 17485512
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1414-1423
pubmed: 31237777
J Exp Med. 2002 Nov 18;196(10):1381-6
pubmed: 12438429
Eur J Immunol. 2011 Oct;41(10):2852-61
pubmed: 21770043
J Exp Med. 2015 May 4;212(5):699-714
pubmed: 25897172
Acta Paediatr. 2014 Aug;103(8):850-5
pubmed: 24766320
Behav Brain Res. 2014 Feb 1;259:253-60
pubmed: 24239696
Eur J Immunol. 2016 Apr;46(4):874-84
pubmed: 26681580
Cell Rep. 2017 Feb 21;18(8):1893-1905
pubmed: 28228256
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Autoimmun. 2014 May;50:107-22
pubmed: 24491821
Allergol Int. 2007 Jun;56(2):157-63
pubmed: 17460443
Nat Commun. 2014 Oct 03;5:5104
pubmed: 25277263
Nat Rev Immunol. 2014 Feb;14(2):81-93
pubmed: 24445666
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Mucosal Immunol. 2019 May;12(3):589-600
pubmed: 30874596
J Infect Dis. 2009 Apr 15;199(8):1128-38
pubmed: 19278337
J Immunol Res. 2017;2017:8734504
pubmed: 29250560
PLoS Pathog. 2017 Sep 27;13(9):e1006640
pubmed: 28953978
Immunity. 2016 Dec 20;45(6):1285-1298
pubmed: 27939673
Immunobiology. 2018 Apr - May;223(4-5):383-396
pubmed: 29146235
Physiol Rev. 2020 Oct 1;100(4):1527-1594
pubmed: 32216549
Expert Rev Anti Infect Ther. 2010 Dec;8(12):1371-80
pubmed: 21133663
J Virol. 2012 Apr;86(8):4505-17
pubmed: 22301139
Clin Exp Immunol. 2013 May;172(2):263-79
pubmed: 23574323
PLoS One. 2012;7(2):e32371
pubmed: 22393401
Front Immunol. 2019 Mar 26;10:566
pubmed: 30972063
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
Mol Med Rep. 2017 Jul;16(1):3-10
pubmed: 28534949
J Virol. 2014 Aug;88(16):9350-60
pubmed: 24920801
Immunity. 2005 Apr;22(4):467-77
pubmed: 15845451
Vaccines (Basel). 2020 Apr 10;8(2):
pubmed: 32290326
Curr Opin Immunol. 2003 Apr;15(2):158-65
pubmed: 12633665
J Leukoc Biol. 2019 May;105(5):891-904
pubmed: 30676652
Allergy. 2020 Apr;75(4):818-830
pubmed: 31622507
Cytokine. 2018 Mar;103:57-62
pubmed: 29324262
J Clin Invest. 1995 Nov;96(5):2445-53
pubmed: 7593633
Immunotherapy. 2011 Apr;3(4 Suppl):19-20
pubmed: 21524162
Int Immunopharmacol. 2015 Dec;29(2):408-415
pubmed: 26603638